Calmark Sweden AB announces the last day of trading in BTU and the first day of trading in warrants of series TO 4 B
Calmark Sweden AB:s ("Calmark" or the "Company") preferential issue of units, with a subscription period that ended on November 10, 2023, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTU (paid subscribed unit) is December 4, 2023, and the stop day is December 6, 2023. The first day of trading in warrants of series TO 4 B is December 8, 2023.
In October/November 2023, Calmark carried out a rights issue which provided the Company with approximately SEK 8.56 million before issue costs. The rights issue has now been registered at the Swedish Companies Registration Office and the last day of trading in BTU is December 4, 2023, and the cut-off date is December 6, 2023. Shares and warrants of series TO 4 B are expected to be distributed to the VP account/depot on December 8, 2023.
After the Swedish Companies Registration Office's registration of the rights issue, the total number of shares in the Company amounts to 104 605 136 (of which 419 400 A-shares) and the share capital to SEK 10,460,513.60. In addition, there are 28,528,668 outstanding warrants of series TO 4 B. The first day of trading in warrants of series TO 4 B is December 8, 2023.
When the offset issue of shares to guarantors has been registered with the Swedish Companies Registration Office, the total number of shares will amount to 112,964,590 shares (of which 419,400 A shares) and the share capital will amount to SEK 11,296,459.00. If the issue of warrants of series TO 4 B to guarantors in the rights issue is approved by the extraordinary general meeting on December 14, 2023, and registered with the Swedish Companies Registration Office, there will be a total of 32,708,395 outstanding warrants of series TO 4 B.
Advisors
Sedermera Corporate Finance AB has in connection with the rights issue assisted Calmark as financial advisor, MAQS Advokatbyrå has assisted as legal advisor and Nordic Issuing AB as issuing agent.
For more information about the Rights Issue, please contact:
Sedermera Corporate Finance AB
Phone: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: